Aggregated News
In an era of commercialized medicine, direct-to-consumer (DTC) genetic testing has been on a steady rise. Consumers can purchase a DNA sample kit, also known as a "spit kit," mail it to a testing company, and wait for an email that reveals their genetic risk for disorders like heart disease and colon cancer. However, a new Yale study reveals that members of the public, as well as physician groups, are concerned about individuals interpreting these risks without the help of a doctor.
"Medical journals have published many editorials expressing concerns about companies that offer genetic tests directly to consumers," said Yale sociologist Rene Almeling, one of the study's authors. "What we did that was new was to ask members of the public whether they thought this was a good idea."
The results of the study confirm that 65% of Americans agree that clinicians should be involved in explaining DTC genetic test results. The study, co-authored by Almeling and Shana Kushner Gadarian from the Maxwell School of Citizenship and Public Affairs at Syracuse University, was published Nov. 7 on the website...